What question did this study set out to answer?

To evaluate the efficacy of motixafortide plus G-CSF versus plerixafor plus G-CSF in poor mobilizers with multiple myeloma.

December 8, 2025BloodOpen Access

Efficacy of motixafortide plus G-CSF versus plerixafor plus G-CSF for stem cell mobilization and collection in multiple myeloma: A single-center comparative analysis and interim Results from a prospective study in poor mobilizers

View Full Paper

Ask AI

Bookmark

Authors

Interim results indicate motixafortide improves stem cell yield in poor mobilizers compared to plerixafor, highlighting efficacy and safety concerns.

To evaluate the efficacy of motixafortide plus G-CSF versus plerixafor plus G-CSF in poor mobilizers with multiple myeloma.
Matched cohorts of MM patients receiving either G-CSF plus motixafortide or plerixafor.
Primary outcomes included apheresis days, collection yield, and adverse reactions.
Statistical analyses employed Mann-Whitney and Student's t-test.
Motixafortide showed a greater fold-increase in pbCD34+ in the poor mobilizer group (21.6 vs 9.1).
Higher median CD34+ yield was observed with motixafortide (4.12 vs 2.09 million cells/kg).
Frequent adverse reactions were recorded with motixafortide, including significant injection site pain.

Sarhan et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Interim results indicate motixafortide improves stem cell yield in poor mobilizers compared to plerixafor, highlighting efficacy and safety concerns.

To evaluate the efficacy of motixafortide plus G-CSF versus plerixafor plus G-CSF in poor mobilizers with multiple myeloma.
Matched cohorts of MM patients receiving either G-CSF plus motixafortide or plerixafor.
Primary outcomes included apheresis days, collection yield, and adverse reactions.
Statistical analyses employed Mann-Whitney and Student's t-test.
Motixafortide showed a greater fold-increase in pbCD34+ in the poor mobilizer group (21.6 vs 9.1).
Higher median CD34+ yield was observed with motixafortide (4.12 vs 2.09 million cells/kg).
Frequent adverse reactions were recorded with motixafortide, including significant injection site pain.

Sarhan et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark